InstalabLoading...
InstalabLoading...
If you have unexplained signs of excess male hormones, such as unusual hair growth, irregular periods, or persistent acne, your 17-OHP (17-hydroxyprogesterone) level can tell you whether the root cause is a genetic enzyme problem in your adrenal glands. This is the single most important blood test for identifying congenital adrenal hyperplasia, or CAH, a condition where your body cannot efficiently make cortisol and instead overproduces androgens. Knowing your 17-OHP level can distinguish CAH from other hormonally similar conditions like polycystic ovary syndrome (PCOS), which matters because the treatments are fundamentally different.
Beyond diagnosis, 17-OHP is also used to monitor how well treatment is controlling the hormonal imbalance in people already known to have CAH. Whether you are investigating symptoms for the first time or tracking a known condition, this test gives you a direct window into how your adrenal glands are functioning.
Your adrenal glands sit on top of your kidneys and produce cortisol, the hormone that helps your body manage stress, blood sugar, and inflammation. To make cortisol, your adrenals run a multi-step assembly line. 17-OHP is one of the intermediate products on that assembly line. It gets made partway through the process when an enzyme called CYP17A1 converts progesterone into 17-OHP.
The next step requires a different enzyme, called 21-hydroxylase, to convert 17-OHP into the molecule that eventually becomes cortisol. If 21-hydroxylase is not working properly, 17-OHP piles up in the blood like packages stuck on a conveyor belt before a broken machine. That buildup is exactly what the test detects.
When 17-OHP accumulates, your body does not simply let it sit there. Instead, it gets diverted into a side pathway that produces androgens, the family of hormones responsible for traits like body hair growth and deepening of the voice. This is why a deficiency in 21-hydroxylase leads to androgen excess and the physical signs that often prompt testing in the first place.
Because 17-OHP follows the daily rhythm of ACTH, the pituitary hormone that drives adrenal activity, your level will be highest in the morning and can fluctuate throughout the day. In women, levels also shift across the menstrual cycle, rising slightly around ovulation and during the luteal phase. For the most accurate reading, the test should be drawn in the morning during the follicular phase (the first half of your cycle, before ovulation).
If you are being evaluated for signs of androgen excess, such as hirsutism (excess hair in a male pattern), acne, thinning scalp hair, or irregular menstrual cycles, 17-OHP is recommended as part of the standard workup. The reason is that non-classic CAH, a milder form that may not become apparent until adolescence or adulthood, can look nearly identical to PCOS. Both conditions can cause hirsutism, irregular periods, and even polycystic-appearing ovaries on ultrasound.
Screening is particularly important if you have a family history of CAH or belong to a population with higher carrier rates, such as people of Ashkenazi Jewish descent. Measuring 17-OHP early in the morning during the follicular phase is the recommended screening approach. If non-classic CAH is confirmed, treatment typically involves low-dose glucocorticoids to replace the cortisol your body struggles to make, which in turn reduces the adrenal drive to overproduce androgens.
This distinction matters because PCOS and non-classic CAH are managed differently. Treating PCOS-like symptoms with oral contraceptives or anti-androgens alone, when the underlying cause is actually an enzyme deficiency, may not address the core problem. Getting the right diagnosis shapes the right treatment.
Because 17-OHP elevation in the context of CAH is caused by a genetic enzyme deficiency, you cannot change the underlying defect through diet or lifestyle. The primary intervention is pharmacological: glucocorticoid replacement therapy. By supplying your body with cortisol (or a synthetic equivalent like hydrocortisone or dexamethasone), you reduce the pituitary's ACTH signal that drives the adrenal glands to overproduce 17-OHP and androgens. Monitoring 17-OHP levels during treatment helps gauge whether your glucocorticoid dose is sufficient to suppress the overactive pathway without over-replacing cortisol.
17-OHP testing is often combined with measurements of testosterone and other androgens to give a fuller picture of hormonal control during treatment. If you are managing CAH, tracking 17-OHP over time helps you and your clinician fine-tune dosing to keep androgen levels in a healthy range while minimizing side effects of glucocorticoid therapy.
17-Hydroxyprogesterone is best interpreted alongside these tests.